Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Swayampakula Ramakanth’s rating is based on Pyxis Oncology’s strategic decision to prioritize PYX-201 ...

The Boston biotech is suspending clinical investments for PYX-106, a candidate Pyxis in-licensed from China-based Biosion in 2022 for $10 million upfront, according to a release shared after ...

- PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and neck squamous cell carcinoma (HNSCC) with additional potential in other ...

Pyxis Oncology said Thursday it will focus resources on its lead asset, PYX-201, which is being studied as a treatment for certain patients with head and neck squamous cell carcinoma, with ...

The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and ...

Pyxis Oncology, Inc. is reallocating its resources to focus on the development of its leading asset, PYX-201, a pioneering antibody-drug conjugate (ADC) showing promising efficacy in treating head ...

In November 2024, Pyxis Oncology reported positive preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating its safety and efficacy in multiple solid tumor types.

Her home town, Itaituba in Brazil’s northern Para state, is at the heart of the country’s illegal gold-mining trade, so a friend suggested raising the money by having sex with miners ...

Seven years ago, El Salvador made global headlines as the first country in the world to ban all metal mining. The decision was hailed as a victory for environmental protection, celebrated by local ...